NCT/Study#

RAPA-201-STP-01

Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of Checkpoint Therapy Resistant Solid Tumors

Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of
Checkpoint Therapy Resistant Solid Tumors

DISEASE GROUP:
Phase 1
current phase:
Phase II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: